Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
ClearPoint Neuro's laser therapy showed improved survival in 14 glioblastoma patients with no complications, pending further validation.
ClearPoint Neuro reported promising results from a Phase I-II study of its ClearPoint Prism Neuro Laser Therapy System in treating aggressive brain tumors like glioblastoma, showing improved survival compared to historical open surgery controls in 14 patients with no device-related complications.
The study, conducted at Skåne University Hospital in Sweden and led by Dr. Peter Siesjö, demonstrated the system’s safety, feasibility, and potential efficacy as a minimally invasive option.
The technology, which uses precise imaging-guided laser ablation, will be showcased at the 75th Annual Congress of Neurological Surgeons in October 2025.
The company’s navigation system is FDA-cleared and CE-marked, with thousands of procedures performed globally.
While the results are encouraging, the company cautioned that future outcomes depend on regulatory, market, and funding factors.
La terapia con láser de ClearPoint Neuro mostró una mejora de la supervivencia en 14 pacientes con glioblastoma sin complicaciones, a la espera de una validación adicional.